Incidence of thrombophilic gene polymorphism (MTHFR C677T) in Egyptian COVID-19 patients and its clinical implications

Abdelfattah, Eman Badawy; Abdelmaksoud, Sahar Samir; Shalaby, Heba Mohamed; Abo-zid, Saad Shehata; Youssef, Mahmoud M. Aboulmagd M.; Elshebiny, Ahmed Ali; Ezzelregal, Hieba Gamal

doi:10.1186/s43168-023-00246-x

The Egyptian Journal of Bronchology

Table 5 Clinical variables linked to the MTHFR gene mutation in the study group

From: Incidence of thrombophilic gene polymorphism (MTHFR C677T) in Egyptian COVID-19 patients and its clinical implications

[n (%)]		MTHFR gene mutation		Test value	P value	Sig
		Absent	Present
		No. = 23	No. = 10
Age	Mean ± SD	42.70 ± 8.39	51.70 ± 12.72	− 2.414^b	0.022	S
Age	Range	25–55	29–67	− 2.414^b	0.022	S
Sex	Female	11 (47.8%)	3 (30.0%)	0.907^a	0.341	NS
Sex	Male	12 (52.2%)	7 (70.0%)	0.907^a	0.341	NS
Smoking	Non-smoker	17 (73.9%)	5 (50.0%)	1.793^a	0.181	NS
Smoking	Smoker	6 (26.1%)	5 (50.0%)	1.793^a	0.181	NS
Fever	No	10 (43.5%)	4 (40.0%)	0.035^a	0.853	NS
Fever	Yes	13 (56.5%)	6 (60.0%)	0.035^a	0.853	NS
Fatigue	No	1 (4.3%)	0 (0.0%)	0.448^a	0.503	NS
Fatigue	Yes	22 (95.7%)	10 (100.0%)	0.448^a	0.503	NS
Bone ache	No	0 (0.0%)	3 (30.0%)	7.590^a	0.006	HS
Bone ache	Yes	23 (100.0%)	7 (70.0%)	7.590^a	0.006	HS
Anosmia	No	14 (60.9%)	7 (70.0%)	0.251^a	0.616	NS
Anosmia	Yes	9 (39.1%)	3 (30.0%)	0.251^a	0.616	NS
Nausea or vomiting	No	11 (47.8%)	6 (60.0%)	0.414^a	0.520	NS
Nausea or vomiting	Yes	12 (52.2%)	4 (40.0%)	0.414^a	0.520	NS
Diarrhea	No	12 (52.2%)	9 (90.0%)	4.309^a	0.038	S
Diarrhea	Yes	11 (47.8%)	1 (10.0%)	4.309^a	0.038	S
Abdominal pain	No	12 (52.2%)	9 (90.0%)	4.309^a	0.038	S
Abdominal pain	Yes	11 (47.8%)	1 (10.0%)	4.309^a	0.038	S
Sore throat	No	14 (60.9%)	7 (70.0%)	0.251^a	0.616	NS
Sore throat	Yes	9 (39.1%)	3 (30.0%)	0.251^a	0.616	NS
Cough	No	14 (60.9%)	5 (50.0%)	0.337^a	0.561	NS
Cough	Yes	9 (39.1%)	5 (50.0%)	0.337^a	0.561	NS
Dyspnea	No	12 (52.2%)	3 (30.0%)	1.382^a	0.240	NS
Dyspnea	Yes	11 (47.8%)	7 (70.0%)	1.382^a	0.240	NS
Diabetes	No	19 (82.6%)	4 (40.0%)	5.991^a	0.014	S
Diabetes	Yes	4 (17.4%)	6 (60.0%)	5.991^a	0.014	S
Hypertension	No	22 (95.7%)	5 (50.0%)	9.764^a	0.002	HS
Hypertension	Yes	1 (4.3%)	5 (50.0%)	9.764^a	0.002	HS
IHD	No	23 (100.0%)	5 (50.0%)	13.554^a	0.000	HS
IHD	Yes	0 (0.0%)	5 (50.0%)	13.554^a	0.000	HS
Chest diseases	No	23 (100.0%)	6 (60.0%)	10.469^a	0.001	HS
Chest diseases	Yes	0 (0.0%)	4 (40.0%)	10.469^a	0.001	HS
Duration of symptoms (days)	Median (IQR)	3 (3–4)	4 (3–7)	− 1.465^c	0.143	NS
Duration of symptoms (days)	Range	2–14	1–11	− 1.465^c	0.143	NS
Need for mechanical ventilation	No	22 (95.7%)	8 (80.0%)	2.066^a	0.151	NS
Need for mechanical ventilation	Yes	1 (4.3%)	2 (20.0%)	2.066^a	0.151	NS
Ward/ICU	No	21 (91.3%)	7 (70.0%)	2.461^a	0.117	NS
Ward/ICU	ICU	2 (8.7%)	3 (30.0%)	2.461^a	0.117	NS
Severity classification	Mild	11 (47.8%)	3 (30.0%)	2.630^a	0.269	NS
	Moderate to Severe	10 (43.5%)	4 (40.0%)
	Critical	2 (8.7%)	3 (30.0%)
HRCT findings	< 50% > 50%	22 (95.7%) 1 (4.3%)	6 (60.0%) 4 (40.0%)	6.891^a	0.009	HS

P value > 0.05 non-significant (NS); P value < 0.05 significant (S); P value < 0.01 highly significant (HS), ICU intensive care unit, HRCT high-resolution computed tomography, IHD ischemic heart disease, IQR Interquartile range, SD Standard deviation
^aChi-square test
^bIndependent t-test
^cMann Whitney test

Back to article page